180 related articles for article (PubMed ID: 29241084)
1. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
von Moos R; Koeberle D; Schacher S; Hayoz S; Winterhalder RC; Roth A; Bodoky G; Samaras P; Berger MD; Rauch D; Saletti P; Plasswilm L; Zwahlen D; Meier UR; Yan P; Izzo P; Klingbiel D; Bärtschi D; Zaugg K;
Eur J Cancer; 2018 Jan; 89():82-89. PubMed ID: 29241084
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Kim R; Prithviraj GK; Shridhar R; Hoffe SE; Jiang K; Zhao X; Chen DT; Almhanna K; Strosberg J; Campos T; Shibata D
Radiother Oncol; 2016 Feb; 118(2):382-6. PubMed ID: 26861740
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
4. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
8. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
9. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
Barsukov YA; Gordeyev SS; Tkachev SI; Fedyanin MY; Perevoshikov AG
Colorectal Dis; 2013 Sep; 15(9):1107-14. PubMed ID: 23668626
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
Jin T; Zhu Y; Luo JL; Zhou N; Li DC; Ju HX; Fan YT; Liu Y; Zhu YP; Feng HY; Liu LY
Int J Colorectal Dis; 2015 Mar; 30(3):337-45. PubMed ID: 25564344
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Salazar R; Capdevila J; Laquente B; Manzano JL; Pericay C; Villacampa MM; López C; Losa F; Safont MJ; Gómez A; Alonso V; Escudero P; Gallego J; Sastre J; Grávalos C; Biondo S; Palacios A; Aranda E
BMC Cancer; 2015 Feb; 15():60. PubMed ID: 25886378
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
14. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J;
Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289
[TBL] [Abstract][Full Text] [Related]
15. Acute Toxicity and Tumor Response in Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy With Shortening of the Overall Treatment Time Using Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost: A Phase 2 Trial.
But-Hadzic J; Anderluh F; Brecelj E; Edhemovic I; Secerov-Ermenc A; Hudej R; Jeromen A; Kozelj M; Krebs B; Oblak I; Omejc M; Vogrin A; Velenik V
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1003-1010. PubMed ID: 27727065
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC
Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Samalin E; Bouché O; Thézenas S; Francois E; Adenis A; Bennouna J; Taieb J; Desseigne F; Seitz JF; Conroy T; Galais MP; Assenat E; Crapez E; Poujol S; Bibeau F; Boissière F; Laurent-Puig P; Ychou M; Mazard T
Br J Cancer; 2014 Mar; 110(5):1148-54. PubMed ID: 24407191
[TBL] [Abstract][Full Text] [Related]
18. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
